Searchable abstracts of presentations at key conferences in endocrinology

ea0031oc5.1 | Pituitary and neoplasia | SFEBES2013

Genetic background influences tumour phenotype in heterozygous Men1 knockout mice

Lines Kate E , Javid Mahsa , Reed Anita A C , Piret Sian E , Walls Gerard V , Stevenson Mark , Christie Paul T , Thakker Rajesh V

Multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder characterised by the occurrence of parathyroid, pancreatic islet and anterior pituitary tumours, is due to mutations of a tumour suppressor gene, MEN1. MEN1 mutations have also been reported to cause familial isolated primary hyperparathyroidism (FIHP). Moreover, 15 identical MEN1 mutations have been reported to cause MEN1 or FIHP in unrelated families; thereby implicating a r...

ea0034p174 | Neoplasia, cancer and late effects | SFEBES2014

Bromodomain inhibitors reduce proliferation and increase apoptosis of human neuroendocrine tumour cells

Lines Kate E , Stevenson Mark , Gaynor Katherine U , Newey Paul J , Piret Sian E , Lingard Hannah , Filippakopoulos Panagis , Muller Susanne , Grozinsky-Glasberg Simona , Grossman Ashley , Knapp Stefan , Schofield Chris , Bountra Chas , Thakker Rajesh V

Pancreatic neuroendocrine tumours (NETs) are reported to show frequent mutations in chromatin remodelling genes, while pituitary NETS have alterations in histone modification. Histone modifications, and specifically acetylated residues on histone tails are recognised by members of the bromo and extra terminal (BET) protein family, via their bromodomains, causing alterations in the transcription of growth stimulating genes. BET bromodomain inhibitors have been demonstrated to s...

ea0031p149 | Neoplasia, cancer and late effects | SFEBES2013

Epigenetic modifiers reduce proliferation of human neuroendocrine tumour cell lines

Lines Kate E , Gaynor Katherine U , Stevenson Mark , Newey Paul J , Piret Sian E , Filippakopoulos Panagis , Muller Susanne , Grozinsky-Glasberg Simona , Grossman Ashley B , Knapp Stefan , Schofield Christopher , Bountra Chas , Thakker Rajesh V

Neuroendocrine tumours (NETs), occurring at multiple sites including the pancreas, gastrointestinal tract, lung, thymus and pituitary, usually present at an advanced metastatic stage, and are increasing in incidence and prevalence as awareness and diagnostic techniques have improved. Treatments for NETs including surgery, drugs (e.g. somatostatin analogues), chemotherapy, radiotherapy and radionuclide therapy, are often not effective and as such additional therapeutic agents a...